SAMN03290888
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.400
- APICAL_JUNCTION+0.300
- APICAL_SURFACE+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- MYC_TARGETS_V2+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- COMPLEMENT+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- HYPOXIA+0.200
Top 10 suppressed
- PROTEIN_SECRETION-0.400
- ANDROGEN_RESPONSE-0.300
- E2F_TARGETS-0.200
- G2M_CHECKPOINT-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- MITOTIC_SPINDLE-0.200
- MTORC1_SIGNALING-0.200
- SPERMATOGENESIS-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290910 | — | — | 0.918 |
| 2 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.877 |
| 3 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.860 |
| 4 | 09f758e5-6be1-4f29-ac92-869d92f8fbcf | — | — | 0.858 |
| 5 | 399cd50c-1439-48a4-ba3b-a0782b2b7b62 | — | — | 0.852 |
| 6 | 40b92a76-f324-4cdd-8209-517d021acd47 | — | — | 0.843 |
| 7 | 44f9e45d-d779-4865-8f10-d085d5d25447 | — | — | 0.823 |
| 8 | SAMN03290915 | — | — | 0.810 |
| 9 | bb3dc2ff-a686-483e-8d3c-e06649462881 | — | — | 0.799 |
| 10 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |